Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company is advancing a product candidate targeting conditions related to pulmonary indications. Savara is conducting clinical trials and pursuing regulatory approval for its pipeline. The company has no currently approved products and relies on third-party manufacturers and clinical research organizations to support its development activities.
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001193125-26-105076 | EDGAR | 69K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-045731 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027920 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010967 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0000950170-22-005045 | EDGAR | — |
| 2021-03-10 | 2020-12-31 | 0001564590-21-011919 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010465 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007585 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001564590-18-005610 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001564590-17-003487 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277525 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107631 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070283 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125292 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095403 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056954 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062040 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041323 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021981 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024458 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016860 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009344 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001193125-26-105099 | EDGAR | 24K words |
| 2026-01-27 | 0001193125-26-023378 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008301 | EDGAR | — |
| 2025-10-30 | 0001193125-25-258629 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256290 | EDGAR | — |
| 2025-09-02 | 0001193125-25-193507 | EDGAR | — |
| 2025-06-06 | 0001193125-25-137150 | EDGAR | — |
| 2025-05-27 | 0001193125-25-126273 | EDGAR | — |
| 2025-03-31 | 0001193125-25-067658 | EDGAR | — |
| 2025-03-26 | 0001193125-25-064145 | EDGAR | — |
412 total filings indexed. 380 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001160308 |
| Ticker | SVRA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.savarapharma.com |
| Listed | 1996-11-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report